Discovery Laboratories (DSCO +8%) climbs today after Stifel Nicolaus initiated coverage earlier with a Buy rating and a $5.00 price target. The firm says the drug developer has two FDA-approved products, Surfaxin and Afectair, both for respiratory distress syndrome, set to launch in Q4. Stifel believes these approvals, along with recent management changes, should help erase the stigma associated with the company's previous FDA rejections.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs